Cancer-Attributable Costs of Diagnosis and Care for Persons with Screen-Detected Versus Symptom-Detected Colorectal Cancer

Scott D. Ramsey, Margaret T. Mandelson, Kristin Berry, Ruth Etzioni, Robert Harrison

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background & Aims: Colorectal cancer screening is effective and cost-effective, but little data from health plan settings are available inform decision-makers regarding direct economic implications of colorectal cancer screening programs. The purpose of this study was to compare the prediagnosis evaluation and first-year treatment costs of persons diagnosed with colorectal cancer, stratified by whether the cancer was detected by screening using fecal occult blood testing or evaluation of symptoms. Methods: This retrospective study analyzed persons diagnosed with colorectal cancer from 1993 to 1999 in Group Health Cooperative, a large health maintenance organization in Washington state. Total health care costs during 3 months before and 12 months following diagnosis were compared for screen-detected versus symptom-detected individuals. Results: During this time, 206 cancers were detected by screening and 717 by symptoms. In the 3 months before diagnosis, total costs were $7346 for persons with screen-detected versus $10,042 for those with symptom-detected cancer (P < 0.01). Stratified by stage, diagnosis costs were significantly lower for persons with stage B cancer ($7282 vs. $11,682; P < 0.01) and nonsignificantly lower for other stages. A total of 53% of screen-detected cases were Dukes' stage A or in situ at diagnosis versus 30% of symptom-detected cases (P < 0.01). Overall costs were lower for the screen-detected group in the 12 months following diagnosis ($22,369 vs. $29,471; P < 0.01). Conclusions: Colorectal cancer screening can substantially reduce prediagnosis evaluation costs. These savings are of interest to health plans and should be factored into cost-effectiveness evaluations of screening programs.

Original languageEnglish (US)
Pages (from-to)1645-1650
Number of pages6
JournalGastroenterology
Volume125
Issue number6
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Costs and Cost Analysis
Early Detection of Cancer
Neoplasms
Health Care Costs
Health
Occult Blood
Symptom Assessment
Health Maintenance Organizations
Program Evaluation
Cost-Benefit Analysis
Retrospective Studies
Economics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cancer-Attributable Costs of Diagnosis and Care for Persons with Screen-Detected Versus Symptom-Detected Colorectal Cancer. / Ramsey, Scott D.; Mandelson, Margaret T.; Berry, Kristin; Etzioni, Ruth; Harrison, Robert.

In: Gastroenterology, Vol. 125, No. 6, 01.01.2003, p. 1645-1650.

Research output: Contribution to journalArticle

Ramsey, Scott D. ; Mandelson, Margaret T. ; Berry, Kristin ; Etzioni, Ruth ; Harrison, Robert. / Cancer-Attributable Costs of Diagnosis and Care for Persons with Screen-Detected Versus Symptom-Detected Colorectal Cancer. In: Gastroenterology. 2003 ; Vol. 125, No. 6. pp. 1645-1650.
@article{85e4a37643be49248529b734483bdfec,
title = "Cancer-Attributable Costs of Diagnosis and Care for Persons with Screen-Detected Versus Symptom-Detected Colorectal Cancer",
abstract = "Background & Aims: Colorectal cancer screening is effective and cost-effective, but little data from health plan settings are available inform decision-makers regarding direct economic implications of colorectal cancer screening programs. The purpose of this study was to compare the prediagnosis evaluation and first-year treatment costs of persons diagnosed with colorectal cancer, stratified by whether the cancer was detected by screening using fecal occult blood testing or evaluation of symptoms. Methods: This retrospective study analyzed persons diagnosed with colorectal cancer from 1993 to 1999 in Group Health Cooperative, a large health maintenance organization in Washington state. Total health care costs during 3 months before and 12 months following diagnosis were compared for screen-detected versus symptom-detected individuals. Results: During this time, 206 cancers were detected by screening and 717 by symptoms. In the 3 months before diagnosis, total costs were $7346 for persons with screen-detected versus $10,042 for those with symptom-detected cancer (P < 0.01). Stratified by stage, diagnosis costs were significantly lower for persons with stage B cancer ($7282 vs. $11,682; P < 0.01) and nonsignificantly lower for other stages. A total of 53{\%} of screen-detected cases were Dukes' stage A or in situ at diagnosis versus 30{\%} of symptom-detected cases (P < 0.01). Overall costs were lower for the screen-detected group in the 12 months following diagnosis ($22,369 vs. $29,471; P < 0.01). Conclusions: Colorectal cancer screening can substantially reduce prediagnosis evaluation costs. These savings are of interest to health plans and should be factored into cost-effectiveness evaluations of screening programs.",
author = "Ramsey, {Scott D.} and Mandelson, {Margaret T.} and Kristin Berry and Ruth Etzioni and Robert Harrison",
year = "2003",
month = "1",
day = "1",
doi = "10.1053/j.gastro.2003.09.032",
language = "English (US)",
volume = "125",
pages = "1645--1650",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Cancer-Attributable Costs of Diagnosis and Care for Persons with Screen-Detected Versus Symptom-Detected Colorectal Cancer

AU - Ramsey, Scott D.

AU - Mandelson, Margaret T.

AU - Berry, Kristin

AU - Etzioni, Ruth

AU - Harrison, Robert

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Background & Aims: Colorectal cancer screening is effective and cost-effective, but little data from health plan settings are available inform decision-makers regarding direct economic implications of colorectal cancer screening programs. The purpose of this study was to compare the prediagnosis evaluation and first-year treatment costs of persons diagnosed with colorectal cancer, stratified by whether the cancer was detected by screening using fecal occult blood testing or evaluation of symptoms. Methods: This retrospective study analyzed persons diagnosed with colorectal cancer from 1993 to 1999 in Group Health Cooperative, a large health maintenance organization in Washington state. Total health care costs during 3 months before and 12 months following diagnosis were compared for screen-detected versus symptom-detected individuals. Results: During this time, 206 cancers were detected by screening and 717 by symptoms. In the 3 months before diagnosis, total costs were $7346 for persons with screen-detected versus $10,042 for those with symptom-detected cancer (P < 0.01). Stratified by stage, diagnosis costs were significantly lower for persons with stage B cancer ($7282 vs. $11,682; P < 0.01) and nonsignificantly lower for other stages. A total of 53% of screen-detected cases were Dukes' stage A or in situ at diagnosis versus 30% of symptom-detected cases (P < 0.01). Overall costs were lower for the screen-detected group in the 12 months following diagnosis ($22,369 vs. $29,471; P < 0.01). Conclusions: Colorectal cancer screening can substantially reduce prediagnosis evaluation costs. These savings are of interest to health plans and should be factored into cost-effectiveness evaluations of screening programs.

AB - Background & Aims: Colorectal cancer screening is effective and cost-effective, but little data from health plan settings are available inform decision-makers regarding direct economic implications of colorectal cancer screening programs. The purpose of this study was to compare the prediagnosis evaluation and first-year treatment costs of persons diagnosed with colorectal cancer, stratified by whether the cancer was detected by screening using fecal occult blood testing or evaluation of symptoms. Methods: This retrospective study analyzed persons diagnosed with colorectal cancer from 1993 to 1999 in Group Health Cooperative, a large health maintenance organization in Washington state. Total health care costs during 3 months before and 12 months following diagnosis were compared for screen-detected versus symptom-detected individuals. Results: During this time, 206 cancers were detected by screening and 717 by symptoms. In the 3 months before diagnosis, total costs were $7346 for persons with screen-detected versus $10,042 for those with symptom-detected cancer (P < 0.01). Stratified by stage, diagnosis costs were significantly lower for persons with stage B cancer ($7282 vs. $11,682; P < 0.01) and nonsignificantly lower for other stages. A total of 53% of screen-detected cases were Dukes' stage A or in situ at diagnosis versus 30% of symptom-detected cases (P < 0.01). Overall costs were lower for the screen-detected group in the 12 months following diagnosis ($22,369 vs. $29,471; P < 0.01). Conclusions: Colorectal cancer screening can substantially reduce prediagnosis evaluation costs. These savings are of interest to health plans and should be factored into cost-effectiveness evaluations of screening programs.

UR - http://www.scopus.com/inward/record.url?scp=0344628831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344628831&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2003.09.032

DO - 10.1053/j.gastro.2003.09.032

M3 - Article

C2 - 14724816

AN - SCOPUS:0344628831

VL - 125

SP - 1645

EP - 1650

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 6

ER -